CA
NZ
UK
AU
IND
US
BioLineRx Ltd. (NASDAQ: BLRX) shares settled up about 7% near $2.78 to $2.80 on Monday, versus Friday's $2.60, on a pipeline-and-runway update.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares settled up about 16%, near $1.78, versus Friday's $1.54, after trading as high as the $2.20s on heavyVolumefollowing news of a constructive FDA Type D meeting held July 28 on the Phase 3 plan for CAD-1005.
NuCana plc (NASDAQ: NCNA) shares settled down about 18%, near $1.45, versus Friday's $1.76, as a sharp Friday rally was sold off in Monday's session.
Corvex (NASDAQ: MOVE), the AI-compute company now using the former Movano ticker, saw shares settle near $11.40 on Monday, roughly flat to about -1% versus Friday's $11.49, after an early spike of more than 40% faded through the session.
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares settled up 12% at $5.66 after the company finished enrollment in COVE-2, the first Phase 3 pivotal study of YCANTH (cantharidin) in common warts.
Kazia Therapeutics Limited (NASDAQ: KZIA) shares settled down 19% at $13.64 after the company priced a public offering of ADSs and warrants that can raise up to $80 million gross if Series A and B warrants are fully exercised.
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares settled down 74% at $0.18 on Monday, August 31, 2026, after the company filed Chapter 11 and put nearly all of itsAssetsup for sale.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares settled down about 25% to 28%, near $3.00 to $3.12, versus Friday's $4.18, after Nasdaq's Listing Qualifications staff told the company on August 27 that it intends to delist the common stock from theCapitalMarket.
Ascentage Pharma Group International (NASDAQ:AAPG) shares fell 5.77% today to $17.23, extending a choppy week marked by extremely thin, low-volume trading typical of the company's limited float. The decline follows the company's August 20 earnings report, which showed a wider than expected quarterly loss …
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares fell 1.64% today to $2.25, moving lower even after the company announced new post hoc data from its Phase 3 SOLOIST-WHF trial showing that sotagliflozin's treatment benefit in heart failure patients held consistent regardless of baseline systolic blood pressure. …
Please wait processing your request...